| Using circulating tumor DNA in colorectal cancer: current and evolving practices M Malla, JM Loree, PM Kasi, AR Parikh Journal of Clinical Oncology 40 (24), 2846, 2022 | 97 | 2022 |
| Sarcomatoid carcinoma of the urinary bladder M Malla, JF Wang, R Trepeta, A Feng, J Wang Clinical Genitourinary Cancer 14 (5), 366-372, 2016 | 52 | 2016 |
| To treat or not to treat: a rare case of pseudo‐thrombotic thrombocytopenic purpura in a Jehovah's Witness M Malla, M Seetharam Transfusion 56 (1), 160-163, 2016 | 20 | 2016 |
| Azacitidine‐induced pericarditis: A case series M Newman, M Malla, I Gojo Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36 (4 …, 2016 | 16 | 2016 |
| Microtubule inhibitors and cardiotoxicity AM Joshi, GS Prousi, C Bianco, M Malla, A Guha, M Shah, SA Brown, ... Current oncology reports 23, 1-8, 2021 | 13 | 2021 |
| Kinetics of postoperative circulating cell-free DNA and impact on minimal residual disease detection rates in patients with resected stage I-III colorectal cancer. SA Cohen, PM Kasi, VN Aushev, DL Hanna, GP Botta, S Sharif, ... Journal of clinical oncology 41 (4_suppl), 5-5, 2023 | 12 | 2023 |
| Immunotherapy in gastroesophageal cancers: current evidence and ongoing trials J Huynh, K Patel, J Gong, M Cho, M Malla, A Parikh, S Klempner Current treatment options in oncology 22, 1-18, 2021 | 12 | 2021 |
| Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers PM Kasi, G Budde, F Dayyani, GP Botta, A Diehl, GT King, M Malla, ... J Clin Oncol 39 (15_suppl), 4103-4103, 2021 | 9 | 2021 |
| Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib JC Avalon, J Fuqua, T Miller, S Deskins, C Wakefield, A King, ... Cardio-Oncology 7, 1-8, 2021 | 8 | 2021 |
| The evolving role of radiation in pancreatic cancer M Malla, F Fekrmandi, N Malik, H Hatoum, S George, RM Goldberg, ... Frontiers in Oncology 12, 1060885, 2023 | 7 | 2023 |
| Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. GP Botta, M Abdelrahim, VN Aushev, A Esmail, B Drummond, S Sharma, ... Journal of Clinical Oncology 40 (4_suppl), 517-517, 2022 | 7 | 2022 |
| Life-threatening immune checkpoint inhibitor-induced myocarditis and myasthenia gravis overlap syndrome treated with abatacept: A case report C Wakefield, C Shultz, B Patel, M Malla BMJ Case Reports CP 14 (11), e244334, 2021 | 6 | 2021 |
| Index admission and thirty-day readmission outcomes of patients with cancer presenting with STEMI M Osman, MM Benjamin, S Balla, B Kheiri, C Bianco, PP Sengupta, ... Cardiovascular Revascularization Medicine 35, 121-128, 2022 | 5 | 2022 |
| 319MO Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer SA Cohen, PM Kasi, VN Aushev, DL Hanna, GP Botta, S Sharif, G Laliotis, ... Annals of Oncology 33, S683-S684, 2022 | 2 | 2022 |
| Updates in the Treatment of Metastatic Colorectal Cancer M Malla, KS Pedersen, AR Parikh JNCCN Journal of the National Comprehensive Cancer Network 21 (55), 567-571, 2023 | 1 | 2023 |
| Comprehensive characterization of mesothelin expression in colorectal cancer. M Malla, SK Deshmukh, S Wu, J Xiu, AP Farrell, HJ Lenz, E Lou, S Goel, ... Journal of Clinical Oncology 41 (4_suppl), 245-245, 2023 | 1 | 2023 |
| Optimal First-Line Therapy for Metastatic Adenocarcinoma of the Esophagus M Malla, J Fuqua, S Mukherjee, RM Goldberg Current Treatment Options in Oncology 23 (12), 1748-1760, 2022 | 1 | 2022 |
| Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Time for a Personalized Approach? A Puleo, M Malla, BA Boone Pancreas 51 (9), 1083-1091, 2022 | 1 | 2022 |
| Neuroendocrine neoplasm of the breast presenting as a liver metastasis: a rare diagnostic challenge M Masab, A Gross, M Flanagan, R Goldberg, M Malla Cureus 13 (8), 2021 | 1 | 2021 |
| Rural and urban disparities based on zip code of residence: Analyses of 834 and 2,159 patients in NCCTG N9741 and CALGB 80405 (Alliance) trials respectively. M Malla, LJ Huebner, S Piawah, HJ Lenz, CD Blanke, JA Meyerhardt, ... Journal of Clinical Oncology 38 (15_suppl), e16076-e16076, 2020 | 1 | 2020 |
